Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 16/20 | 0.76 |
| ▸ | HTR1D | P28221 | 8/20 | 0.76 |
| ▸ | HTR1B | P28222 | 7/20 | 0.76 |
| ▸ | HTR2C | P28335 | 12/20 | 0.65 |
| ▸ | HTR2A | P28223 | 5/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 4/20 | 0.63 |
| ▸ | HTR1E | P28566 | 3/20 | 0.63 |
| ▸ | HTR1F | P30939 | 3/20 | 0.63 |
| ▸ | HTR7 | P34969 | 3/20 | 0.63 |
| ▸ | HTR3A | P46098 | 3/20 | 0.63 |
| ▸ | HTR5A | P47898 | 3/20 | 0.63 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.63 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.62 |
| ▸ | HTR3B | O95264 | 2/20 | 0.62 |
| ▸ | HTR6 | P50406 | 2/20 | 0.62 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612481 | 0.87 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL31574201 | 0.87 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL13653014 | 0.85 | HTR1A (0.81) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL1750326 | 0.85 | HTR1A (0.76) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL15701887 | 0.85 | HTR1A (0.76) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL5320736 | 0.85 | KDM4E (0.57) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL2998441 | 0.85 | HTR1A (0.71) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL10745433 | 0.83 | HTR6 (0.69) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL13647702 | 0.83 | HTR1A (0.72) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL10717762 | 0.82 | HTR1D (0.67) | HTR1AHTR1DHTR1BHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| EP-1883451-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | RATIOPHARM GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR1A 91/4885HTR1D 511/4885HTR1B 221/4885 |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR1A 91/4885HTR1D 511/4885HTR1B 221/4885 |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | HTR7, HRH4, CA7 | HTR1A 31/4885HTR1D 48/4885HTR1B 147/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | HTR1A 91/4885HTR1D 511/4885HTR1B 221/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR1A 91/4885HTR1D 511/4885HTR1B 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.